Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenny L Valentine

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|June 4, 2026
Immunogenicity assessment for vidutolimod: a risk-driven approach for a simplified 1-tiered, singlicate anti-drug antibody testing strategyJenny L Valentine, Stacey Shank, Lisette M Fred Lucena, et al.
Cell Chemical Biology|June 25, 2016
Immunization with Outer Membrane Vesicles Displaying Designer Glycotopes Yields Class-Switched, Glycan-Specific AntibodiesJenny L Valentine, Linxiao Chen, Emily C Perregaux, et al.
Journal of Clinical Pharmacology|September 1, 2023
Immunogenicity of Cemiplimab: Low Incidence of Antidrug Antibodies and Cut-Point Suitability Across Tumor TypesJenny L Valentine, Andrew Dengler, An Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 9, 2016
Outer membrane vesicles displaying engineered glycotopes elicit protective antibodiesLinxiao Chen, Jenny L Valentine, Chung-Jr Huang, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|June 4, 2026
Immunogenicity assessment for vidutolimod: a risk-driven approach for a simplified 1-tiered, singlicate anti-drug antibody testing strategyJenny L Valentine, Stacey Shank, Lisette M Fred Lucena, et al.
Cell Chemical Biology|June 25, 2016
Immunization with Outer Membrane Vesicles Displaying Designer Glycotopes Yields Class-Switched, Glycan-Specific AntibodiesJenny L Valentine, Linxiao Chen, Emily C Perregaux, et al.
Journal of Clinical Pharmacology|September 1, 2023
Immunogenicity of Cemiplimab: Low Incidence of Antidrug Antibodies and Cut-Point Suitability Across Tumor TypesJenny L Valentine, Andrew Dengler, An Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 9, 2016
Outer membrane vesicles displaying engineered glycotopes elicit protective antibodiesLinxiao Chen, Jenny L Valentine, Chung-Jr Huang, et al.
Pageof 1